Sequenom's Shares Soar on Launch of Fetal Sex Determination Test

The firm's shares eclipsed the $5 mark for the first time since last year's dismissal of its CEO and other executives following an investigation into the mishandling of test data on its Down Syndrome test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories